semaglutide cardiovascular outcomes news and in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category | Diabetes Therapy Cardiovascular outcomes of semaglutide and

Your endocrinologist prescribed Soliqua 100/33, combining long-acting insulin with a GLP-1 receptor agonist in one injection

In macrophages deficient in the cystine/glutamate antiporter xCT, CysSSH levels were significantly reduced compared with those in wild-type macrophages, probably because of an insufficient availability of CysSH as a substrate

Other options include Zepbound , Saxenda , and Qsymia

Implications for GLP-1 drugmakers and pharmacies: The two dominant weight loss drug makers, Novo Nordisk and Eli Lilly, have mostly figured out how to meet escalating consumer demand for GLP-1s

& Druker, B

This third mechanism adds a layer of GI disruption on top of the GLP-1-mediated delayed gastric emptying that both drugs share